risperidone has been researched along with Cerebrovascular Disorders in 11 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data from all double-blind randomised controlled trials of risperidone in dementia patients (risperidone n = 1009, placebo n = 712) were included." | 8.93 | Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. ( Berlin, JA; Coppola, D; Costafreda, SG; Hough, D; Howard, R; Karcher, K, 2016) |
| "Clozapine may alleviate hyperactivity in the limbic system in schizophrenia and may facilitate activation of the regions involved in cognitive tasks to a greater degree than risperidone, as well as eliciting greater inhibition of the PF region." | 7.74 | Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. ( De Luxán, A; Domínguez-Gil, A; Martin, C; Molina, V; Montes, C; Rivas, N; Sancho, C; Tamayo, P, 2008) |
| "In March 2004, the UK Committee of Safety of Medicines (CSM) informed clinicians that risperidone and olanzapine should not be used to treat behavioural and psychological symptoms of dementia (BPSD) because of increased risk of strokes with both drugs and increased risk of mortality with olanzapine." | 7.73 | Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued? ( Shah, A, 2006) |
| "Data from all double-blind randomised controlled trials of risperidone in dementia patients (risperidone n = 1009, placebo n = 712) were included." | 4.93 | Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. ( Berlin, JA; Coppola, D; Costafreda, SG; Hough, D; Howard, R; Karcher, K, 2016) |
| "Clozapine may alleviate hyperactivity in the limbic system in schizophrenia and may facilitate activation of the regions involved in cognitive tasks to a greater degree than risperidone, as well as eliciting greater inhibition of the PF region." | 3.74 | Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. ( De Luxán, A; Domínguez-Gil, A; Martin, C; Molina, V; Montes, C; Rivas, N; Sancho, C; Tamayo, P, 2008) |
| "In March 2004, the UK Committee of Safety of Medicines (CSM) informed clinicians that risperidone and olanzapine should not be used to treat behavioural and psychological symptoms of dementia (BPSD) because of increased risk of strokes with both drugs and increased risk of mortality with olanzapine." | 3.73 | Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued? ( Shah, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kar, SK | 1 |
| Saxena, S | 1 |
| Trivedi, JK | 1 |
| Howard, R | 1 |
| Costafreda, SG | 1 |
| Karcher, K | 1 |
| Coppola, D | 1 |
| Berlin, JA | 1 |
| Hough, D | 1 |
| Forlenza, OV | 1 |
| Cretaz, E | 1 |
| Diniz, BS | 1 |
| Chan, MC | 1 |
| Chong, CS | 1 |
| Wu, AY | 1 |
| Wong, KC | 1 |
| Dunn, EL | 1 |
| Tang, OW | 1 |
| Chan, WF | 1 |
| Ballard, C | 1 |
| Cream, J | 1 |
| Formiga, F | 2 |
| Fort, I | 2 |
| Pérez-Castejón, JM | 2 |
| Ruiz, D | 2 |
| Duaso, E | 2 |
| Riu, S | 2 |
| Finkel, S | 1 |
| Kozma, C | 1 |
| Long, S | 1 |
| Greenspan, A | 1 |
| Mahmoud, R | 1 |
| Baser, O | 1 |
| Engelhart, L | 1 |
| Shah, A | 1 |
| Burns, A | 1 |
| De Deyn, PP | 1 |
| Molina, V | 1 |
| Tamayo, P | 1 |
| Montes, C | 1 |
| De Luxán, A | 1 |
| Martin, C | 1 |
| Rivas, N | 1 |
| Sancho, C | 1 |
| Domínguez-Gil, A | 1 |
3 reviews available for risperidone and Cerebrovascular Disorders
| Article | Year |
|---|---|
Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients.
Topics: Antipsychotic Agents; Cerebrovascular Disorders; Dementia; Humans; Risperidone | 2016 |
[The use of antipsychotics in patients with dementia].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebrovascular Disorders; Dementia; Dementia, | 2008 |
Risperidone for the treatment of neuropsychiatric features in dementia.
Topics: Accidental Falls; Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Cognitio | 2006 |
8 other studies available for risperidone and Cerebrovascular Disorders
| Article | Year |
|---|---|
Electroconvulsive treatment in catatonia of cerebrovasculo-coagulopathy: a case report.
Topics: Adult; Antipsychotic Agents; Catatonia; Cerebrovascular Disorders; Depression, Postpartum; Electroco | 2013 |
Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Dementia; Female; Hong Kon | 2010 |
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.
Topics: Accidental Falls; Aged; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cognition; | 2005 |
Association between risperidone treatment and cerebrovascular adverse events in elderly patients with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Dementia; Female; Humans; | 2005 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort St | 2005 |
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cardiovascular | 2006 |
[Risperidone and cerebrovascular adverse effects in elderly patients with dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Cholinesterase Inhibitors; | 2006 |
Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Brain; Cerebrovascular Disorders; Clozapine; Cognition; Drug Resistance | 2008 |